drug
discoveri
develop
broadspectrum
antivir
agent
bsaa
b
r
c
viral
diseas
one
lead
caus
morbid
mortal
world
virusspecif
vaccin
antivir
drug
power
tool
combat
viral
diseas
howev
broadspectrum
antivir
agent
bsaa
ie
compound
target
virus
belong
two
viral
famili
could
provid
addit
protect
gener
popul
emerg
reemerg
viral
diseas
reinforc
arsen
avail
antivir
option
review
discoveri
develop
bsaa
summar
inform
safeinman
agent
freeli
access
databas
http
drugvirusinfo
futur
ongo
preclin
clinic
studi
increas
number
bsaa
expand
spectrum
indic
identifi
drug
combin
treatment
emerg
reemerg
viral
infect
well
coinfect
virus
one
major
caus
morbid
mortal
world
dali
collabor
diseas
et
al
howard
fletcher
antivir
drug
vaccin
use
fight
viral
infect
human
de
clercq
li
marston
et
al
previous
focu
one
drug
one
viru
dogma
reli
target
virusspecif
factor
counterpoint
one
drug
multipl
virus
paradigm
came
discoveri
broadspectrum
antivir
agent
bsaa
smallmolecul
inhibit
wide
rang
human
virus
bekerman
einav
de
clercq
montgomeri
debe
et
al
ianevski
et
al
rada
dragun
sidwel
et
al
paradigm
base
observ
differ
virus
util
similar
pathway
host
factor
replic
insid
cell
bosl
et
al
although
concept
bsaa
around
almost
year
field
receiv
new
impetu
recent
outbreak
ebola
zika
dengu
influenza
viral
infect
discoveri
novel
hostdirect
agent
well
develop
drug
reposit
methodolog
drug
repurpos
also
call
reposit
redirect
reprofil
strategi
gener
addit
valu
exist
drug
target
diseas
origin
intend
nishimura
hara
pushpakom
et
al
signific
advantag
new
drug
discoveri
sinc
chemic
synthesi
step
manufactur
process
reliabl
safeti
pharmacokinet
properti
preclin
anim
model
earli
clinic
development
phase
phase
iia
alreadi
avail
figur
therefor
reposit
launch
even
fail
drug
viral
diseas
provid
uniqu
translat
opportun
includ
substanti
higher
probabl
success
market
compar
develop
new
virusspecif
drug
vaccin
significantli
reduc
cost
timelin
clinic
avail
pizzorno
et
al
zheng
et
al
detail
step
bsaa
repurpos
discoveri
novel
antivir
activ
cell
cultur
postmarket
studi
moreov
summar
current
avail
inform
bsaa
freeli
avail
databas
focus
antivir
alreadi
test
human
antivir
antibacteri
antiprotozo
anthelmint
etc
final
discuss
futur
perspect
use
safeinman
bsaa
treatment
emerg
reemerg
viral
infect
well
viral
bacteri
coinfect
discoveri
novel
bsaa
activ
immort
cell
cultur
cocultur
discoveri
novel
activ
bsaa
start
expos
cell
candid
antivir
agent
differ
concentr
infect
cell
viru
mock
immort
cancer
cell
cultur
cocultur
express
appropri
viral
receptor
commonli
use
first
step
halfmaxim
cytotox
concentr
cc
compound
calcul
base
doserespons
curv
obtain
mockinfect
cell
halfmaxim
effect
concentr
ec
calcul
base
analysi
curv
obtain
infect
cell
statist
analys
help
determin
differ
cc
ec
signific
given
inher
variabl
experi
meneghini
hamasaki
rel
effect
drug
defin
select
index
si
cc
ec
cell
viabil
assay
cell
death
assay
commonli
use
assess
cytotox
efficaci
bsaa
figur
cell
viabil
assay
includ
mtt
mt
resazurin
similar
assay
mitochondri
membran
potentialdepend
dyesbas
assay
esteras
cleav
dyebas
assay
atpadp
assay
assay
measur
glycolyt
flux
oxygen
consumpt
cell
death
assay
includ
ldh
enzym
leakag
assay
membran
imperm
dyebas
assay
apoptosi
assay
annexin
v
tunel
caspas
assay
shen
et
al
exampl
cell
titer
glo
ctg
assay
quantifi
atp
indic
metabol
activ
live
cell
wherea
cell
tox
green
assay
use
fluoresc
asymmetr
cyanin
dye
stain
dna
dead
cell
bosl
et
al
bulanova
et
al
ianevski
et
al
muller
et
al
viral
strain
cell
line
express
report
protein
also
use
assess
efficaci
bsaa
infect
cell
exampl
tzmbl
cell
express
firefli
luciferas
control
ltr
promot
allow
quantit
bsaa
action
infect
tatprotein
express
integr
proviru
use
firefli
luciferas
assay
sarzottikelso
et
al
xing
et
al
rfpexpress
rvfv
nanolucexpress
chikv
rrv
well
gfpexpress
fluav
hcv
hmpv
also
allow
identif
novel
activ
sever
bsaa
andersen
et
al
bosl
et
al
de
graaf
et
al
habjan
et
al
ianevski
et
al
jupil
et
al
kittel
et
al
lee
et
al
utt
et
al
addit
qpcrrtqpcr
rnadna
sequenc
rnadna
hybrid
immunoand
plaqu
assay
well
system
could
use
detect
inhibitori
effect
bsaa
boonham
et
al
fischer
et
al
konig
et
al
laamiri
et
al
landri
perez
et
al
sashit
zhou
et
al
interestingli
sirna
shrna
approach
use
identif
bsaa
target
dean
et
al
puschnik
et
al
novel
activ
emetin
discov
recent
use
ctgplaqu
assay
human
nonmalign
rpe
cell
moreov
novel
antivir
activ
drug
identifi
use
rfpexpress
rvfv
gfpexpress
hmpv
fluav
strain
rpe
cell
andersen
et
al
given
emetin
also
inhibit
zikv
ebov
rabv
cmv
infect
chave
valadao
et
al
macgibeni
et
al
mukhopadhyay
et
al
shen
et
al
yang
et
al
fdaapprov
antiprotozo
drug
may
repres
promis
safeinman
bsaa
candid
immort
cell
culturescocultur
report
viral
strain
repres
excel
model
system
discoveri
novel
activ
safeinman
bsaa
howev
genet
modifi
system
certain
limit
attenu
incomplet
viru
replic
cycl
accumul
mutat
repeat
cell
viru
passag
defect
innat
immun
respons
viral
counterrespons
etc
carter
shieh
therebi
novel
antivir
activ
bsaa
valid
primari
human
cell
use
differ
viral
strain
includ
wildtyp
virus
differ
viral
load
differ
time
compound
addit
differ
endpoint
measur
compound
concentr
rang
primari
cell
cultur
give
accur
imag
drug
respons
alv
et
al
denisova
et
al
koban
et
al
postnikova
et
al
low
popul
doubl
level
therefor
close
recapitul
physiolog
condit
observ
vivo
primari
cell
cell
isol
directli
tissu
blood
use
enzymat
mechan
method
cell
character
high
degre
special
often
fulli
differenti
thu
requir
defin
cultur
condit
serumfre
media
order
preserv
origin
phenotyp
peripher
blood
mononuclear
pbmc
placent
amniot
fetal
primari
cultur
well
vaginalcerv
epitheli
male
germ
cell
use
intens
valid
bsaa
activ
barrow
et
al
denisova
et
al
fink
et
al
rausch
et
al
robinson
et
al
although
primari
cell
cultur
relev
system
valid
bsaa
technic
difficulti
limit
use
ethic
issu
puriti
popul
primari
cell
limit
shelf
life
cell
addit
age
race
sex
genet
epigenet
factor
donor
cell
consid
determin
common
biolog
effect
across
signific
number
donor
therebi
avoid
minor
variant
lee
et
al
zhang
et
al
obstacl
associ
use
human
primari
cell
cultur
bypass
use
human
embryon
stem
cell
esc
human
induc
pluripot
stem
cell
ipsc
esc
isol
surplu
human
embryo
wherea
ipsc
obtain
reprogram
somat
cell
cell
prolifer
extens
retain
multilineag
activ
allow
gener
virtual
cell
type
bodi
escsand
ipscderiv
cell
use
success
investig
efficaci
sever
bsaa
hbv
zikv
chikv
infect
tabl
ferreira
et
al
iwasawa
et
al
lanko
et
al
simonin
et
al
xia
et
al
zhou
et
al
ipsc
esc
primari
tissu
cell
use
gener
complex
cultur
term
organoid
organoid
miniatur
simplifi
version
organ
establish
human
airway
gut
skin
cerebr
liver
kidney
breast
retina
brain
organoid
allow
research
studi
toxic
efficaci
sever
safeinman
bsaa
coronavirus
influenza
enterovirus
rotavirus
flavivirus
sacramento
et
al
watanab
et
al
xu
et
al
yin
et
al
yin
et
al
yin
et
al
zhou
et
al
howev
ipsc
esc
ipscsescsderiv
organoid
disadvantag
human
primari
cell
genet
differ
linetolin
organoid
batchtobatch
variabl
hand
model
allow
research
predict
behavior
virus
vivo
therefor
reduc
anim
use
case
anim
model
unavail
initi
clinic
trial
exampl
novel
antizikv
activ
enoxacin
amodiaquin
niclosamid
discov
recent
use
human
neural
progenitor
cell
human
pluripot
stem
cellderiv
cortic
neural
progenitor
cell
human
induc
neural
stem
cell
respect
cairn
et
al
xu
et
al
zhou
et
al
enoxacin
oral
broadspectrum
fluoroquinolon
antibiot
also
possess
antihcv
activ
immort
cell
cultur
kashiwas
et
al
young
et
al
amodiaquin
antimalaria
drug
also
possess
antivir
activ
denv
hcv
rrv
sinv
wnv
efv
ebov
lasv
rabv
vzv
immort
cell
cultur
boonyasuppayakorn
et
al
hulseberg
et
al
mazzon
et
al
niclosamid
oral
bioavail
anthelmint
drug
inhibit
broadest
rang
virus
vitro
drug
reposit
anoth
diseas
ie
safeti
profil
man
avail
could
bypass
pk
safeti
studi
man
case
vivo
cairn
et
al
fang
et
al
huang
et
al
hulseberg
et
al
jurgeit
et
al
kao
et
al
mazzon
et
al
stachulski
et
al
wang
et
al
wu
et
al
safeinman
bsaa
repres
promis
drug
candid
vitro
ex
vivo
model
fulli
reflect
complex
physiolog
live
organ
therefor
sever
vivo
model
develop
test
novel
antivir
activ
bsaa
includ
immunocompet
genet
chemic
immunocompromis
mice
guinea
pig
hamster
ferret
pig
macaqu
anim
figur
alv
et
al
haes
et
al
louz
et
al
morrison
diamond
taylor
thangavel
bouvier
pkpd
studi
determin
drug
absorpt
dosag
halflif
bsaa
toxicolog
studi
determin
drug
advers
effect
tissu
organ
anim
defin
dosag
advers
effect
alabast
vivo
pharmacolog
train
group
parasuraman
rizk
et
al
studi
efficaci
bsaa
gener
done
treat
anim
drug
vehicl
infect
viru
interest
endpoint
usual
bodi
weight
mortal
depend
viru
histopatholog
viru
titer
organ
presenc
clinic
sign
develop
immun
oh
hurt
smee
barnard
although
anim
model
give
initi
character
bsaa
import
keep
mind
differ
significantli
human
respect
symptom
diseas
manifest
suscept
immun
respons
pathogenesi
pharmacokinet
montagutelli
shank
et
al
often
anim
requir
higher
concentr
experiment
antivir
compar
effect
vitro
concentr
moreov
rel
difficult
achiev
micromolar
vivo
exampl
aminoglycosid
antibiot
kasugamycin
neomycin
success
test
zikv
fluav
infect
mice
gopinath
et
al
polyeth
antibiot
salinomycin
also
show
antifluav
effect
mice
jang
et
al
addit
investig
anticanc
agent
flavopiridol
effect
fluav
mice
find
support
develop
bsaa
clinic
trial
critic
timeconsum
step
drug
candid
journey
approv
figur
howev
safeinman
bsaa
make
journey
rel
short
alreadi
phase
sometim
iia
clinic
trial
antibacteri
antiprotozo
anticanc
etc
agent
ie
administ
subtherapeut
dose
healthi
volunt
ensur
drug
harm
particip
thu
safeinman
bsaa
enter
phase
ii
iii
assess
efficaci
effect
safeti
side
effect
drug
clinic
import
howev
differenti
acut
chronic
viral
infect
repurpos
bsaa
given
drug
concentr
durat
treatment
could
differ
therefor
drug
safeti
issu
consid
phase
ii
patient
viral
diseas
question
invit
join
studi
administ
bsaa
ideal
therapeut
dose
phase
iii
longest
phase
includ
multipl
level
secur
studi
use
placebo
doubleblind
studi
ensur
data
unbias
possibl
upon
complet
phase
iii
depend
perform
efficaci
bsaa
may
end
either
approv
drop
us
food
drug
administr
fda
estim
bsaa
candid
enter
phase
iii
approv
use
public
us
food
drug
administr
approv
market
drug
phase
iv
may
initi
follow
use
drug
public
surveil
rare
effect
us
food
drug
administr
umscheid
et
al
fortyeight
safeinman
bsaa
undergo
clinic
studi
antivir
current
compound
phase
agent
phase
ii
compound
phase
iii
clinic
trial
exampl
nitazoxanid
remdesivir
brincidofovir
clinic
investig
differ
viral
infect
twentyon
bsaa
approv
fda
ema
agenc
bsaa
altogeth
target
virus
exampl
favipiravir
also
known
approv
fluav
japan
cidofovir
inject
antivir
medic
use
treatment
cmv
retin
peopl
aid
ribavirin
also
known
tribavirin
use
treatment
rsv
hcv
infect
pleconaril
use
virus
picornavirida
famili
includ
enteroviru
rhinoviru
valacyclovir
use
cmv
ebv
hbv
vzv
infect
twenti
bsaa
undergo
surveil
studi
phase
iv
azithromycin
chloroquin
cyclosporin
ezetimib
mycophenol
acid
nitazoxanid
rapamycin
progress
phase
iv
studi
without
approv
nation
intern
author
develop
databas
safeinman
bsaa
avail
http
drugvirusinfo
figur
drug
annot
obtain
pubchem
drugbank
drugcentr
pubm
clinicaltrialsgov
databas
tabl
ursu
et
al
wishart
et
al
inform
viru
famili
export
viru
pathogen
databas
analysi
resourc
tabl
pickett
et
al
databas
summar
activ
development
statu
bsaa
decid
set
limit
si
statist
signific
studi
harmon
differ
cell
line
assay
endpoint
measur
time
compound
addit
etc
databas
allow
interact
explor
virusbsaa
interact
also
includ
inform
bsa
target
feedback
form
avail
websit
databas
updat
upon
request
soon
new
safeinman
bsaa
emerg
novel
activ
exist
bsaa
report
altogeth
databas
contain
approv
investig
experiment
safeinman
bsaa
inhibit
human
virus
belong
viral
famili
bsaa
inhibit
viral
host
factor
block
viral
replic
reduc
viral
burden
level
host
immun
respons
deal
facilit
apoptosi
infect
cell
tabl
analysi
bsaa
target
structur
figur
reveal
abund
nucleotid
nucleosid
analogu
inhibit
viral
rna
dna
polymeras
imatinib
erlotinib
gefitinib
dasatinib
inhibit
tyrosin
kinas
abund
hostdirect
bsaa
host
target
except
bclxl
protein
essenti
viral
replic
redund
cell
critic
reduc
put
toxic
associ
block
cellular
pathway
limit
divers
target
scaffold
could
slow
develop
bsaa
concept
emerg
bsaa
saliphenylhalamid
denisova
et
al
kuivanen
et
al
muller
et
al
muller
et
al
patil
et
al
sheahan
et
al
whose
safeti
profil
human
yet
avail
includ
databas
howev
could
serv
valuabl
antivir
futur
pend
result
preclin
clinic
investig
novel
strain
coronavirus
associ
cluster
case
pneumonia
china
zhou
et
al
coronavirus
cov
broad
famili
virusesthat
includ
sarscov
merscov
strain
strain
usual
associ
mild
selflimit
upper
respiratori
tract
infect
common
cold
contrast
peopl
infect
merscov
sasrscov
could
develop
sever
respiratori
ill
mani
infect
die
vaccin
drug
avail
prevent
prophylaxi
treatment
coronaviru
infect
human
eurosurveil
editori
howev
safeinman
bsaa
could
effect
coronavirus
figur
exampl
teicoplanin
oritavancin
dalbavancin
monensin
emetin
could
repurpos
treatment
teicoplanin
ritavancin
dalbavancin
monensin
approv
antibiot
wherea
emetin
antiprotozo
drug
drug
shown
inhibit
sever
coronaa
well
viral
infect
moreov
chloroquin
remdesivir
shown
effect
inhibit
infect
vitro
addit
clinic
investig
effect
lopinavir
ritonavir
remdesivir
hydroxychloroquin
arbidol
start
recent
bsaa
could
combin
antivir
agent
obtain
synergist
addit
effect
certain
virus
zheng
et
al
sever
combin
therapi
includ
bsaa
abacavirdolutegravirlamivudin
triumeq
darunavircobicistatemtricitabinetenofovir
symtuza
lopinavirritonavir
kaletra
ledipasvirsofosbuvir
sofosbuvirvelpatasvir
becam
standard
treatment
hiv
hcv
infect
sever
synergist
drug
combin
obatoclaxsaliphenylhalamid
gemcitabinepimodivir
could
enter
clinic
studi
becom
effect
treatment
zikv
fluav
infect
fu
et
al
kuivanen
et
al
contrast
individu
drug
combin
bsaa
could
use
target
even
broader
rang
virus
foucquier
guedj
zheng
et
al
combin
could
serv
front
line
therapeut
poorli
character
emerg
virus
reemerg
drugresist
viral
strain
exampl
cocktail
nitazoxanid
favipiravir
niclosamid
could
develop
treatment
virus
belong
famili
fifti
bsaa
possess
antivir
also
antibacteri
activ
figur
tabl
schor
einav
moreov
agent
approv
antibiot
withdrawn
agent
dual
activ
could
use
treatment
viral
bacteri
coinfect
protect
patient
secondari
infect
exampl
azithromycin
could
use
fluav
chlamydophila
pneumonia
haemophilu
influenza
mycoplasma
pneumonia
streptococcu
pneumonia
infect
mandel
et
al
addit
bsaa
show
activ
wide
rang
medic
import
human
pathogen
includ
fungi
protozoa
parasit
tabl
montoya
krysan
point
pathogen
util
common
mechan
infect
host
moreov
structureact
relationship
analysi
bsaa
suggest
agent
doxycyclin
artesun
omeprazol
nitazoxanid
suramin
azithromycin
minocyclin
chloroquin
could
novel
antibacteri
antiprotozo
antifung
anthelmint
activ
figur
confirm
could
lead
develop
broadspectrum
antiinfect
drug
bsaa
could
also
serv
treatment
comorbid
therefor
simplifi
therapi
lower
cost
tabl
exampl
concomit
action
ezetimib
statin
could
benefici
treatment
hypertens
sever
viral
infect
patient
comorbid
review
process
bsaa
develop
summar
inform
safeinman
agent
freeli
avail
databas
hope
preclin
clinic
studi
bsaa
harmon
data
collect
standard
furthermor
followup
studi
well
result
ongo
final
termin
clinic
trial
made
publicli
avail
allow
priorit
translat
emerg
exist
bsaa
clinic
practic
would
allow
bsaa
play
pivot
role
battl
emerg
reemerg
viral
diseas
discoveri
novel
well
reposit
exist
safeinman
bsaa
may
shorten
time
resourc
need
develop
virusspecif
drug
vaccin
futur
bsaa
global
impact
decreas
morbid
mortal
viral
diseas
maxim
number
healthi
life
year
improv
qualiti
life
infect
patient
decreas
cost
patient
care
author
declar
conflict
interest
studi
support
european
region
develop
fund
mobilita
pluss
project
dk
approv
requir
thank
katarzyna
kolasa
illustr
manuscript
releas
preprint
doi
http
thank
european
region
develop
fund
mobilita
pluss
project
figur
safeinman
broadspectrum
antivir
agent
coronavirus
inhibit
snapshot
taken
http
drugvirusinfo
websit
differ
shade
indic
differ
develop
statu
bsaa
grey
shade
indic
antivir
activ
either
studi
report
